Benitec Biopharma (BNTC) Total Non-Current Liabilities (2025)
Benitec Biopharma's (BNTC) quarterly Total Non-Current Liabilities came in at $3.3 million in Q4 2025, up 44.54% quarter-over-quarter from $2.3 million in Q2 2025.
Benitec Biopharma (BNTC) Total Non-Current Liabilities (2025) Analysis & Trends
Benitec Biopharma has disclosed Total Non-Current Liabilities across 1 years of filings, most recently posting $3.3 million for Q4 2025.
- Total Non-Current Liabilities for Q4 2025 came in at $3.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $3.3 million (changed N/A YoY), and the FY2025 annual result was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities came in at $3.3 million for Q4 2025 at Benitec Biopharma, up from $2.3 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $3.3 million in Q4 2025 to a low of $2.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 42,980.09 |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 64.76 Mn |
| 10 | Benitec Biopharma | 488.21 Mn | 488.21 Mn | - | 3.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.32 Mn |
| Jun 30, 2025 | 2.30 Mn |